Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report

Pembrolizumab for treatment-related neuroendocrine prostate carcinoma with a high tumor mutational burden: a case report

Pembrolizumab has emerged as a significant therapeutic option for the treatment of solid tumors with a high tumor mutational burden (TMB-high). However, there have been no reports of its use in treatment-related neuroendocrine prostate carcinoma (t-NEPC) with TMB-high. We present the case of a 66-ye...

Full description

Saved in:

Bibliographic Details
Main Authors:	Keiji Shiba, Motohiro Fujiwara, Ayaka Onuki, Daisuke Kato, Takeshi Shirakawa, Yohei Shimizu, Takumasa Amemiya, Tsunehiro Nenohi, Yuki Matsumoto, Masayasu Urushibara, Hideto Kano, Kazuhiro Ishizaka, Mikiko Takahashi, Minato Yokoyama
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-08-01
Series:	Frontiers in Oncology
Subjects:	pembrolizumab prostate cancer tumor mutational burden treatment-related neuroendocrine prostate carcinoma immune checkpoint inhibitors
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1642412/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Long‐Term Survival Obtained by Repeated Cytoreductive Surgery and S‐1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report
by: Masayasu Urushibara, et al.
Published: (2025-08-01)

Robust response to pembrolizumab plus lenvatinib in a patient with renal cell carcinoma with rhabdoid features: A case report
by: Shinkuro Yamamoto, et al.
Published: (2025-09-01)

Pembrolizumab‐Induced Anti‐Yo‐Antibody‐Positive Cerebellitis: A Case Report
by: Takafumi Yamano, et al.
Published: (2025-03-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Fusion Biopsy, not Cognitive, Is the New Gold Standard
by: Alessandro Marquis, et al.
Published: (2023-03-01)

Pembrolizumab promotes degradation of cyclin dependent kinase 6 and suppresses ovarian cancer progression in vitro
by: Yi Wu, et al.
Published: (2025-07-01)

Prostate cancer diagnosis and management: current practices in Africa a consultant-based survey
by: Marcella Derboise Christelle Biyouma, et al.
Published: (2025-03-01)

COMPARATIVE EVALUATION OF CURRENT METHODS OF ANESTHESIA IN PERFORMANCE OF TRANSRECTAL PROSTATE BIOPSY
by: M. E. Topuzov, et al.
Published: (2015-10-01)

Prognostic Impact of Clostridium butyricum MIYAIRI (CBM588) in Combination With Pembrolizumab for Advanced Urothelial Carcinoma: A Retrospective Cohort Study
by: Junya Arima, et al.
Published: (2025-08-01)

Real-world outcomes after pembrolizumab treatment for cervical cancer: Results from a university setting
by: Rachel L. Furuya, et al.
Published: (2025-08-01)

Current biomarkers of prostate cancer
by: I. A. Aboian, et al.
Published: (2021-12-01)

Usefulness of prostate specific antigen density in detecting prostate carcinoma: A hospital-based study in patients with prostate biopsies
by: Reshmi Shrestha, et al.
Published: (2022-03-01)

OPEN RADICAL RETROPUBIC PROSTATECTOMY
by: M. B. Chibichyan
Published: (2018-03-01)

The role of glucose transporter type 1 (GLUT1) and carbonic anhydrase IX (CAIX) expression by prostate adenocarcinoma tissue in determining disease prognosis and effectiveness of radical treatment
by: S. V. Vovdenko, et al.
Published: (2023-01-01)

Re-irradiation with concurrent pembrolizumab for local-regionally recurrent squamous cell carcinoma of the head and neck
by: Allen M. Chen, et al.
Published: (2025-03-01)

Therapeutic Indications of Pembrolizumab in Eight Common Cancers: Current Evidence and Future Directions
by: Raghed Mansour, et al.
Published: (2025-07-01)

Multi-omic insights into mitochondrial dysfunction and prostatic disease: evidence from transcriptomics, proteomics, and methylomics
by: Binbin Gong, et al.
Published: (2025-08-01)

Lenvatinib in combination with pembrolizumab as first-line therapy for advanced endometrial cancer: clinical case
by: E. A. Khachaturyan, et al.
Published: (2025-05-01)

Optimization of HIFU monotherapy for prostate cancer
by: K. V. Pozdnyakov, et al.
Published: (2022-04-01)

COMPUTER TOMOGRAPHY IN DIAGNOSIS OF DISEASES AND NEW FORMATIONS OF THE PROSTATE GLAND
by: D. E. Baikov, et al.
Published: (2017-07-01)

Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature
by: Kazuaki Harada, et al.
Published: (2020-05-01)

Aortoesophageal fistula following thoracic branch endoprosthesis for cryptogenic penetrating aortic ulcer in a patient on pembrolizumab
by: Sarah Kim, BA, et al.
Published: (2025-08-01)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024-01-01)

Pharmacoeconomic analysis of therapy with brentuximab vedotin, nivolumab and pembrolizumab in patients with relapsed Hodgkin’s lymphoma
by: N. A. Avxentyev, et al.
Published: (2020-12-01)

The long-term clinical efficacy and safety of lenvatinib plus pembrolizumab in endometrial cancer: data from routine clinical practice in Russia
by: A. E. Protasova, et al.
Published: (2024-11-01)

Neoadjuvant prostate artery embolization prior to prostate radiation therapy: A single institution experience on the durability of clinical urinary improvement after radiation
by: Vaseem M. Khatri, et al.
Published: (2025-11-01)

Metastatic bone lesions of men in combination with an increase in serum PSA from the point of view of diagnosing carcinomas of unknown primary localization
by: O. V. Poslavska, et al.
Published: (2019-05-01)

A Case Report and Literature Review of Prostatic Tuberculosis Masquerading as Prostate Cancer: A Diagnostic Challenge in a Tuberculosis-Endemic Region
by: Yonathan William, et al.
Published: (2025-05-01)

Pelvic space-occupying lesion with lower urinary tract symptoms diagnosed as inflammatory myofibroblastic tumor of the prostate with a review of the literature
by: Shashank Shukla, et al.
Published: (2024-05-01)

THE PROGNOSTIC VALUE OF BASELINE PSA BLOOD IN THE TREATMENT OF PROSTATE CANCER
by: A. A. Gritskevich, et al.
Published: (2017-02-01)

HistoScanning<sup>TM</sup> vs. standard multifocal biopsy for prostate cancer diagnosis: a comparison of diagnostic methods
by: S. V. Kotov, et al.
Published: (2023-12-01)

Increased GPR35 expression is correlated with poor prognosis in prostate cancer
by: Tianyi Zhang, et al.
Published: (2025-06-01)

Experience in the use of MRI-ultrasound fusion-targeted biopsy of the prostate for the diagnosis of prostate cancer
by: E. S. Nevirovich, et al.
Published: (2018-10-01)

The Rebound Effect of the COVID-19 Pandemic on Clinically Significant Prostate Cancer Diagnosis
by: Antonio Fanelli, et al.
Published: (2025-03-01)

Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01)

Efficacy and safety of combination therapy with lenvatinib and pembrolizumab in elderly patients with advanced endometrial cancer
by: M. V. Volkonskiy, et al.
Published: (2025-05-01)

Use of a BMI-independent biomarker-based prostate cancer risk score to identify and triage individuals at risk of prostate disease
by: Joanne Watt, et al.
Published: (2025-07-01)

Association of Serum PSA, fPSA, and CEA Levels with Prognosis and Clinicopathological Characteristics in Prostate Cancer
by: Ahamed Y, et al.
Published: (2025-08-01)

Efficacy and safety of lenvatinib plus pembrolizumab in patients with endometrial cancer: data from an extended study of routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2025-03-01)

Pembrolizumab plus chemotherapy in advanced endometrial cancer: a cost-effectiveness analysis
by: Xinqiang Zhao, et al.
Published: (2025-06-01)